Tagged: biopharma M&A

Pharmaceutical industry stands at a crossroads today. Between 2018 and November 2024, shareholders saw just 7.6% returns on the PwC pharma index, while the S&P 500 delivered more than 15% . This gap grew even wider last year, with pharma’s 13.9% return falling well short...